![Podcast thumbnail for Expose MASH [Formerly NASH]](https://pod-engine-public.nyc3.cdn.digitaloceanspaces.com/images/FscXw7pPYb9pIkXbgryvMLmw35MxAZNv65pFlY0Rbg5.png)
by Novo Nordisk
Recent advances in understanding steatotic liver disease have revealed overlapping biological processes that may contribute to non-alcoholic fatty liver disease (NAFLD). Join us in this podcast series where your colleagues will take you on a journey to better understand the cardiometabolic basis for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), which has long been recognized as “the hepatic manifestation of the metabolic syndrome.” In this series, we will explore MASH, including epidemiology, pathophysiology, comorbidities, patients at risk, and HCP perspectives on the patient journey. This series is tailored specifically for healthcare professionals seeking deeper insights into MASH. Expose MASH [Formerly NASH] is tailored for healthcare professionals seeking to stay at the forefront of liver disease knowledge. This podcast is sponsored by Novo Nordisk and is intended for U.S. clinicians. This podcast is not to be used as medical advice.
Language
🇺🇲
Publishing Since
7/8/2024
Email Addresses
1 available
Phone Numbers
0 available
December 10, 2024
Liver specialists, Dr. [Last Name] and Dr. [Last Name], highlight the urgency of MASH screening to prevent fibrosis progression and reduce associated morbidity and mortality.
October 17, 2024
In this episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we will share insights on the current MASH guidelines. The adoption of the new MASH nomenclature, with the inclusion of cardiometabolic risk factors into its formal definition, will be briefly discussed before examining the different clinical guidelines that are available. We will identify shared recommendations and key points of difference for the screening and management of this complex disease. We will then look to the future to discuss how emerging data may inform future guidelines and help optimize clinical practice. This episode is brought to you by Novo Nordisk Inc.
October 2, 2024
In this sixth episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we share insight on primary fibrosis risk assessment using the FIB-4 index in patients with MASH (metabolic dysfunction-associated steatohepatitis). Our experts explain the importance of noninvasive tests as a useful tool to identify patients at high risk for MASH. Futhermore, they discuss the relevance of using the FIB-4 test in order to facilitate timely intervention for these at-risk patients. This episode is brought to you by Novo Nordisk Inc.
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.